Staff could be in line for vaccine booster jabs

2021 ◽  
Vol 28 (4) ◽  
pp. 7-7
Keyword(s):  
Vaccine Booster

scholarly journals Safety and Immunogenicity of Heptavalent Pneumococcal Conjugate Vaccine Booster in Taiwanese Toddlers

2006 ◽  
Vol 105 (7) ◽  
pp. 542-549 ◽  
Author(s):  
Pei-Lan Shao ◽  
Po-Ren Hsueh ◽  
Chun-Yi Lu ◽  
Luan-Yin Chang ◽  
Fu-Yuan Huang ◽  
...  
Keyword(s):  
Conjugate Vaccine ◽  
Pneumococcal Conjugate Vaccine ◽  
Vaccine Booster ◽  
Heptavalent Pneumococcal Conjugate Vaccine

scholarly journals Pneumococcal Nasopharyngeal Carriage following Reduced Doses of a 7-Valent Pneumococcal Conjugate Vaccine and a 23-Valent Pneumococcal Polysaccharide Vaccine Booster

2010 ◽  
Vol 17 (12) ◽  
pp. 1970-1976 ◽  
Author(s):  
F. M. Russell ◽  
J. R. Carapetis ◽  
C. Satzke ◽  
L. Tikoduadua ◽  
L. Waqatakirewa ◽  
...  
Keyword(s):  
Conjugate Vaccine ◽  
Pneumococcal Conjugate Vaccine ◽  
Polysaccharide Vaccine ◽  
Dose Effect ◽  
Pneumococcal Polysaccharide Vaccine ◽  
Pneumococcal Carriage ◽  
Primary Series ◽  
Vaccine Type ◽  
Vaccine Booster ◽  
Antibody Levels

ABSTRACT This study was conducted to evaluate the effect of a reduced-dose 7-valent pneumococcal conjugate vaccine (PCV) primary series followed by a 23-valent pneumococcal polysaccharide vaccine (23vPPS) booster on nasopharyngeal (NP) pneumococcal carriage. For this purpose, Fijian infants aged 6 weeks were randomized to receive 0, 1, 2, or 3 PCV doses. Within each group, half received 23vPPS at 12 months. NP swabs were taken at 6, 9, 12, and 17 months and were cultured for Streptococcus pneumoniae. Isolates were serotyped by multiplex PCR and a reverse line blot assay. There were no significant differences in PCV vaccine type (VT) carriage between the 3- and 2-dose groups at 12 months. NP VT carriage was significantly higher (P, <0.01) in the unvaccinated group than in the 3-dose group at the age of 9 months. There appeared to be a PCV dose effect in the cumulative proportion of infants carrying the VT, with less VT carriage occurring with more doses of PCV. Non-PCV serotype (NVT) carriage rates were similar for all PCV groups. When groups were pooled by receipt or nonreceipt of 23vPPS at 12 months, there were no differences in pneumococcal, VT, or NVT carriage rates between the 2 groups at the age of 17 months. In conclusion, there appeared to be a PCV dose effect on VT carriage, with less VT carriage occurring with more doses of PCV. By the age of 17 months, NVT carriage rates were similar for all groups. 23vPPS had no impact on carriage, despite the substantial boosts in antibody levels.

scholarly journals Combating pertussis resurgence: One booster vaccination schedule does not fit all

2015 ◽  
Vol 112 (5) ◽  
pp. E472-E477 ◽  
Author(s):  
Maria A. Riolo ◽  
Pejman Rohani
Keyword(s):  
Booster Vaccination ◽  
Cost Effective ◽  
Vaccination Schedule ◽  
Health Concern ◽  
Transmission Model ◽  
Public Health Concern ◽  
Vaccine Failure ◽  
Vaccination Strategies ◽  
Vaccine Booster ◽  
Pertussis Epidemiology

Pertussis has reemerged as a major public health concern in many countries where it was once considered well controlled. Although the mechanisms responsible for continued pertussis circulation and resurgence remain elusive and contentious, many countries have nevertheless recommended booster vaccinations, the timing and number of which vary widely. Here, using a stochastic, age-stratified transmission model, we searched for cost-effective booster vaccination strategies using a genetic algorithm. We did so assuming four hypothesized mechanisms underpinning contemporary pertussis epidemiology: (I) insufficient coverage, (II) frequent primary vaccine failure, (III) waning of vaccine-derived protection, and (IV) vaccine “leakiness.” For scenarios I–IV, successful booster strategies were identified and varied considerably by mechanism. Especially notable is the inability of booster schedules to alleviate resurgence when vaccines are leaky. Critically, our findings argue that the ultimate effectiveness of vaccine booster schedules will likely depend on correctly pinpointing the causes of resurgence, with misdiagnosis of the problem epidemiologically ineffective and economically costly.

Inactivated hepatitis A vaccine booster given ≥24 months after the primary dose

Vaccine ◽  
2000 ◽  
Vol 19 (4-5) ◽  
pp. 399-402 ◽  
Author(s):  
P. Landry ◽  
S. Tremblay ◽  
R. Darioli ◽  
B. Genton
Keyword(s):  
Hepatitis A ◽  
Primary Dose ◽  
Vaccine Booster

A Randomized, Multicenter, Open-Label Clinical Trial to Assess the Immunogenicity of a Meningococcal C Vaccine Booster Dose Administered to Children Aged 14 to 18 Months

2010 ◽  
Vol 29 (2) ◽  
pp. 148-152 ◽  
Author(s):  
Javier Díez-Domingo ◽  
M Victoria Planelles Cantarino ◽  
Jose M. Baldó Torrentí ◽  
M Isabel Úbeda Sansano ◽  
Angels Jubert Rosich ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Booster Dose ◽  
Open Label ◽  
Vaccine Booster

scholarly journals Androgenetic alopecia may be associated with weaker COVID-19 T-cell immune response: An insight into a potential COVID-19 vaccine booster

2020 ◽  
pp. 110439 ◽  
Author(s):  
Andy Goren ◽  
Flavio Adsuara Cadegiani ◽  
Carlos Gustavo Wambier ◽  
Sergio Vano-Galvan ◽  
Antonella Tosti ◽  
...  
Keyword(s):  
Immune Response ◽  
T Cell ◽  
Androgenetic Alopecia ◽  
Cell Immune Response ◽  
Vaccine Booster ◽  
Insight Into
Sign in / Sign up

Export Citation Format

Share Document